Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway

Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway

Background/Aims: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignant tumors with poor prognosis. Conventional chemotherapies including gemcitabine have failed owing to weak response and side effects. Hence novel treatment regimens are urgently needed to improve the therapeuti...

Full description

Bibliographic Details
Main Authors: Zhenghuan Fang, Kyung Hee Jung, Hong Hua Yan, Soo-Jung Kim, Marufa Rumman, Jung Hee Park, Boreum Han, Ji Eun Lee, Yeo wool Kang, Joo Han Lim, Soon Sun Hong
Format: Article
Language:English
Published: Cell Physiol Biochem Press GmbH & Co KG 2018-06-01
Series:Cellular Physiology and Biochemistry
Subjects:
Sorafenib
Melatonin
Pancreatic cancer
Apoptosis
PDGFR-β/STAT3
Online Access:https://www.karger.com/Article/FullText/491058

Internet

https://www.karger.com/Article/FullText/491058

Similar Items